Cancers Treated:
Specializing In:
- Understanding subtypes of CRPC and developing novel therapeutic strategies
Positions
Roswell Park Comprehensive Cancer Center
- Research Assistant Professor of Oncology
- Affiliate Member
- Department of Pharmacology & Therapeutics
Background
Education and Training
- 2015 - PhD - University of the Punjab, Lahore, Pakistan
Professional Memberships
- AACR
Honors & Awards
- Pre-Doctoral-IRSIP fellowship, Higher Education Commission of Pakistan
- Lecturer Position, Lahore University of Management Sciences
Research Overview
My research centers on exploring the heterogeneity of prostate cancer, including castration-resistant prostate cancer (CRPC), with the goal of developing new therapeutic strategies. A significant part of my work also involves investigating the tumor immune microenvironment, which plays a critical role in disease progression and response to treatment.
In studying the complex cellular diversity within the prostate gland and CRPC, I used advanced techniques such as PhenoImager, and Image Mass Cytometry (IMC) to gain a detailed understanding of the cellular dynamics and interactions. These high-content imaging approaches allow me to visualize and analyze the complex behavior of various cells in the tumor and its surrounding immune microenvironment, providing deeper insights into mechanisms of resistance and response to therapy. By focusing on these interactions, I aim to uncover mechanisms that contribute to treatment resistance and apply this knowledge to design more effective therapeutic options.
Additionally, I have been involved in the study of assessing patient responsiveness to novel combinational prostate cancer treatment. This involves isolating and analyzing circulating tumor cells (CTCs) through liquid biopsies, which provide a real-time window into how patients are responding to therapy. Together, these research efforts aim to create a more personalized approach to treating prostate cancer, targeting both the tumor cells and their surrounding immune environment.
Publications
1. Jamroze A*, Chatta G, Tang DG*. (2021) Androgen receptor heterogeneity in prostate cancer and therapy resistance. Cancer Lett. 10; 518:1-9 (*Co-corresponding authors).
2. Jamroze A, Liu X, Tang DG. Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance. Cancer Heterog Plast. 2024;1(1):0005. doi: 10.47248/chp2401010005. Epub 2024 Aug 25. PMID: 39363904
3. Jason S Kirk, Jie Wang, Amanda Tracz, Mark Long, Spencer Rosario, Yibing Ji, Rahul Kumar, Xiaozhuo Liu, Anmbreen Jamroze, Prashant K Singh, Igor Puzanov, Gurkamal Chatta, Qing Cheng, Jiaoti Huang, Jeffrey L Wrana, Jonathan Lovell, Han Yu, Song Liu, Michael M Shen, Tao Liu, Dean G Tang. (2024) Integrated single cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. Cell Stem Cell 31(8):1203-1221, 2024. PMID: 38878775.
4. Fan T, Xu C, Wu J, Cai Y, Cao W, Shen H, Zhang M, Zhu H, Yang J, Zhu Z, Ma X, Ren J, Huang L, Li Q, Tang Y, Yu B, Chen C, Xu M, Wang Q, Xu Z, Chen F, Liang S, Zhong Z, Jamroze A, Tang DG, Li H, Dong C. Lipopolyplex formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity, Sci Adv. 2024 Oct 11;10(41):eadn9961. doi: 10.1126/sciadv.adn9961. Epub 2024 Oct 11.PMID: 39392882
5. Li F, Ling X, Chakraborty S, Fountzilas C, Wang J, Jamroze A, Liu X, Kalinski P, Tang DG. (2023) Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence. J Exp Clin Cancer Res.42(1):213.